Interventions to Improve Oral Chemotherapy Safety and Quality

Zerillo, Jessica A.; Goldenberg, Benjamin; Kotecha, Ritesh; Tewari, Alok K.; Jacobson, Joseph O.; Krzyzanowska, Monika K.

doi:10.1001/jamaoncol.2017.0625

Cited by 68 publications

(64 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It seems that interventions that are aimed at improving symptom reporting may be more useful than those aimed at improving nonadherence as a result of other reasons—for example, reminder systems used to address nonadherence as a result of forgetfulness. 31 , 56 …”

Section: Monitoring and Follow-upmentioning

confidence: 99%

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

Mackler

Segal

Muluneh

et al. 2019

JOP

View full text Add to dashboard Cite

PURPOSE: The aim of the current work was to present a pharmacy practice standard from the Hematology/Oncology Pharmacy Association (HOPA) on the management of oral oncolytic therapy. METHODS: The HOPA Standards Committee organized a work group of oncology pharmacist specialists to create a pharmacy practice standard for the management of oral oncolytic therapy that describes the pharmacist’s role on the cancer care team, provides examples of practice tools and resources, summarizes current data related to outcomes, and discusses opportunities to enhance the care of patients with cancer who receive oral oncolytic therapy. We reviewed primary literature, including currently published oral oncolytic guidelines and HOPA’s Scope of Hematology/Oncology Pharmacy Practice. RESULTS: Management of oral oncolytic therapy was divided into the following primary areas: prescribing, education, dispensing and distribution, and monitoring and follow-up. Pharmacists’ roles were summarized in each area with a focus on interprofessional collaboration, communication, patient safety, and quality of patient care. Standards describe the best practices in each area ( Table 1 ). CONCLUSION: Multiple opportunities exist for pharmacists to enhance the care of patients with cancer who receive oral oncolytics through collaboration with oncology care team members. The role of the oncology pharmacist in the care of this patient population is critical given the complexities related to cost, tolerability, and safety of oral oncolytic medications; issues of access; and the monitoring and follow-up of patients receiving this therapy.

show abstract

Section: Monitoring and Follow-upmentioning

confidence: 99%

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

Mackler

Segal

Muluneh

et al. 2019

JOP

View full text Add to dashboard Cite

show abstract

“…O emprego de tecnologias educativas validadas reforça o processo de ensino-aprendizagem e estreita a comunicação entre o profissional de saúde e o paciente. Ainda, contribui para o empoderamento do paciente, promovendo o autocuidado e reduzindo os erros de medicação, afetando positivamente os resultados terapêuticos 18,19,25,26 .…”

Section: Discussionunclassified

Validação de Materiais Educativos para Orientação de Pacientes em Tratamento de Câncer de Mama com Hormonioterapia

Sugisaka¹,

Andrzejevski

Rotta

2020

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

Introdução: A baixa adesão ao tratamento com antineoplásicos orais reflete a necessidade de medidas que facilitem o cumprimento da terapia, como a provisão de materiais educativos. Objetivo: Desenvolver e validar cartilhas orientando o uso dos medicamentos tamoxifeno, anastrozol e capecitabina no tratamento do câncer de mama. Método: Para a definição do conteúdo das cartilhas, foram consultadas as bases de dados MEDLINE e UpToDate, e as diretrizes nacionais e internacionais, adotando-se linguagem acessível ao público. A validação foi feita por especialistas em oncologia, por meio do método Delphi, considerando-se os atributos de linguagem, conteúdo e aparência. Um consenso satisfatório foi atingido quando o valor de faixa interquartil (FIQ) foi ≤ 1, obtido por meio de uma escala Likert variando de 1 a 5. Resultados: O grupo de especialistas foi composto por 29 profissionais. Na primeira rodada, foi obtida uma FIQ de 1,43; 1,14 e 1,43; e, na segunda rodada, 0,71; 1,04 e 0,79 para linguagem, conteúdo e aparência, respectivamente. Conclusão: Espera-se que essas ferramentas promovam melhor percepção e adesão do paciente ao tratamento, contribuindo para a autogestão da farmacoterapia.

show abstract

“…The CNs of the OTC involved outside healthcare professionals in patient care irrespective of cancer or drug type. To the best of our knowledge, few organisations have used CNs, and hospital and town pharmacists and doctors, to manage oral therapies for all types of cancer patients [ 19 ]. Interventions included education, monitoring, administration, telephone calls, and physical assessments; high-risk patients often do not receive so much attention [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)

et al. 2020

View full text Add to dashboard Cite

Oral therapies have highly modified cancer patient management and changed hospital practises. We introduce a specific Oral Therapy Centre and retrospectively review information prospectively recorded by co-ordination nurses (CNs) (the DICTO programme). We describe the roles played by CNs in the management of oral cancer therapies at Limoges Dupuytren Hospital between May 2015 and June 2018. All cancers, irrespective of stage or whether oral general chemotherapy or targeted therapy was prescribed, are included. We followed up 287 patients of median age 67 years (range 26–89 years). Of these, 76% had metastases and 44% were on first-line therapy. The vast majority (88%) of their first CN contacts occurred just after physician consultation and lasted an average of 60 min. As part of follow-up, the CNs made 2719 calls (average 10 min) to patients to educate them and to verify compliance and drug tolerance. They also received 833 calls from patients (70%) or their relatives or health professionals (30%) seeking advice on management of side effects. In addition to the initial appointments, 1069 non-scheduled follow-up visits were made to assess side effects (49.2%). The CNs devoted 5 h to each patient over 3 months of treatment (i.e. 25 min/day) and, also organised scheduled hospitalisations in the department of oncology for 51% of patients. We show the interest and real-life work in a specific oral therapy centre within oncology department with the role of CNs to facilitate the global health care of the patients. Electronic supplementary material The online version of this article (10.1007/s12032-020-01393-7) contains supplementary material, which is available to authorized users.

show abstract

Interventions to Improve Oral Chemotherapy Safety and Quality

Cited by 68 publications

References 64 publications

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

Validação de Materiais Educativos para Orientação de Pacientes em Tratamento de Câncer de Mama com Hormonioterapia

Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)

Contact Info

Product

Resources

About